

Cerus Corp (CERS) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/C4CF5D6B8F9EN.html>

Date: June 2020

Pages: 59

Price: US\$ 125.00 (Single User License)

ID: C4CF5D6B8F9EN

Abstracts

Cerus Corp (CERS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes Intercept Blood System, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for use with three blood components, : platelets, plasma and red blood cells. Cerus' Intercept blood system is marketed and sold by its direct sales force and distributors in several countries worldwide including the US, Belgium, Kuwait, France, Spain, Portugal, Switzerland, Commonwealth of Independent States (CIS) countries and other countries. Cerus is headquartered in Concord, California, the US.

Cerus Corp Key Recent Developments

May 05,2020: Cerus announces first quarter 2020 results

Apr 06,2020: Cerus provides update on COVID-19 related activities

Apr 02,2020: Cerus Corporation announces the inclusion of pathogen reduction technology in the ISBT working party recommendations for the preparation of COVID-19 convalescent plasma

Mar 02,2020: Cerus announces strategic organizational changes

Jan 13,2020: Cerus Announces Preliminary Fourth Quarter and Full Year 2019 Product

Revenue

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Cerus Corp - Key Facts
Cerus Corp - Key Employees
Cerus Corp - Key Employee Biographies
Cerus Corp - Major Products and Services
Cerus Corp - History
Cerus Corp - Company Statement
Cerus Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Cerus Corp - Business Description
Business Segment: Government Contract Revenue
Performance
Business Segment: Product Revenue
Performance
Geographical Segment: Belgium
Performance
Geographical Segment: France
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: The US
Performance
Cerus Corp - SWOT Analysis
SWOT Analysis - Overview
Cerus Corp - Strengths
Cerus Corp - Weaknesses
Cerus Corp - Opportunities
Cerus Corp - Threats
Cerus Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Cerus Corp (CERS) - Financial and Strategic SWOT Analysis Review

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cerus Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Cerus Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Cerus Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 05, 2020: Cerus announces first quarter 2020 results

Apr 06, 2020: Cerus provides update on COVID-19 related activities

Apr 02, 2020: Cerus Corporation announces the inclusion of pathogen reduction technology in the ISBT working party recommendations for the preparation of COVID-19 convalescent plasma

Mar 02, 2020: Cerus announces strategic organizational changes

Jan 13, 2020: Cerus Announces Preliminary Fourth Quarter and Full Year 2019 Product Revenue

Oct 30, 2019: Cerus announces third quarter 2019 results

Aug 01, 2019: Cerus announces record second quarter 2019 results

Jun 03, 2019: Cerus announces new corporate brand and global headquarters

May 07, 2019: Cerus announces record first quarter 2019 results

Mar 05, 2019: Cerus names Jami Nachtsheim as Board Director

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Cerus Corp, Key Facts
Cerus Corp, Key Employees
Cerus Corp, Key Employee Biographies
Cerus Corp, Major Products and Services
Cerus Corp, History
Cerus Corp, Subsidiaries
Cerus Corp, Key Competitors
Cerus Corp, Ratios based on current share price
Cerus Corp, Annual Ratios
Cerus Corp, Annual Ratios (Cont...1)
Cerus Corp, Interim Ratios
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Cerus Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Cerus Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Cerus Corp, Performance Chart (2015 - 2019)

Cerus Corp, Ratio Charts

Cerus Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Cerus Corp, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Grifols SA

Kedrion Biopharma Inc

Terumo BCT Inc

Octapharma AG

MacoPharma International GmbH

I would like to order

Product name: Cerus Corp (CERS) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/C4CF5D6B8F9EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4CF5D6B8F9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970